Review



lambda zap ii vector  (Agilent technologies)


Bioz Verified Symbol Agilent technologies is a verified supplier
Bioz Manufacturer Symbol Agilent technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Agilent technologies lambda zap ii vector
    Lambda Zap Ii Vector, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/us11932908-1092-12-16
    Average 90 stars, based on 1 article reviews
    lambda zap ii vector - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Lambdoid bacteriophage vectors for expression of foreign proteins
    Article Snippet: Exemplary vectors are the lambda vectors EMBL3, EMBL4, FIX, FIX® II, DASH, DASH® II, ZAP, ZAP® II, and ZAP ExpressTM available from Stratagene (La Jolla, Calif.) and ExCell available from Pharmacia, (Piscataway, N.J.).

    Article Title: DNA encoding mammalian phosphodiesterases
    Article Snippet: The cDNA (25–50 ng per μg vector) was ligated into EcoRI-digested, dephosphorylated ZAP® II (Stratagene) arms [Short et al., Nuc.

    Article Title: Lambdoid bacteriophage vectors for expression of foreign proteins
    Article Snippet: Exemplary vectors are the lambda vectors EMBL3, EMBL4, FIX, FIX® II, DASH, DASH® II, ZAP, ZAP® II, and ZAP ExpressTM available from Stratagene (La Jolla, Calif.) and ExCell available from Pharmacia, (Piscataway, N.J.).



    Similar Products

    lambda zap ii vector  (Agilent technologies)
    90
    Agilent technologies lambda zap ii vector
    Lambda Zap Ii Vector, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/us11932908-1092-12-16
    Average 90 stars, based on 1 article reviews
    lambda zap ii vector - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    lambda zap ii phage vector  (Agilent technologies)
    90
    Agilent technologies lambda zap ii phage vector
    Lambda Zap Ii Phage Vector, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/us11778965-890-20-35
    Average 90 stars, based on 1 article reviews
    lambda zap ii phage vector - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    αhexokinase ii  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc αhexokinase ii
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    αhexokinase Ii, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/Phospho-Zap-70+(Tyr319)%2FSyk+(Tyr352)+Antibody/pmc10347457-146-4-26
    Average 95 stars, based on 1 article reviews
    αhexokinase ii - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    lambda zap ii  (Agilent technologies)
    90
    Agilent technologies lambda zap ii
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    Lambda Zap Ii, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/pmc01334188-152-15-20
    Average 90 stars, based on 1 article reviews
    lambda zap ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    λ zap ii library  (TaKaRa)
    96
    TaKaRa λ zap ii library
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    λ Zap Ii Library, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/Lambda-EcoT14+I%2FBgl+II+Digest/pmc00552957-28-1-5
    Average 96 stars, based on 1 article reviews
    λ zap ii library - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    lamda zap ii bacteriophage vector  (Agilent technologies)
    90
    Agilent technologies lamda zap ii bacteriophage vector
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    Lamda Zap Ii Bacteriophage Vector, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/pmc01408080-189-23-28
    Average 90 stars, based on 1 article reviews
    lamda zap ii bacteriophage vector - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    λ zap ii  (Agilent technologies)
    90
    Agilent technologies λ zap ii
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    λ Zap Ii, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/pmc02633016-169-14-17
    Average 90 stars, based on 1 article reviews
    λ zap ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    λ-zap vector ii kit  (Agilent technologies)
    90
    Agilent technologies λ-zap vector ii kit
    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or <t>hexokinase</t> 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.
    λ Zap Vector Ii Kit, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zap%C2%AE+ii/pmc02245808-163-17-21
    Average 90 stars, based on 1 article reviews
    λ-zap vector ii kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or hexokinase 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

    doi: 10.1136/jitc-2023-006785

    Figure Lengend Snippet: Validation of ikarugamycin as a dendritic cell (DC) stimulator. (A) Bone marrow-derived dendritic cells (BMDCs) were treated with ikarugamycin (IKA; 1 µM) or astemizole (AST; 1 µM) for 16 hours then DC activation and maturation was analyzed by flow cytometry, 1 µg/mL of lipopolysaccharide (LPS) was used as positive control. (B, C) BMDCs were treated with IKA (0.2, 0.5, 1, 2 µM) for 16 hours, then cells were harvested, and proteins were detected by western blot. (D–E) Representative western blot images (D) and quantification (E) of control (Ctr) or hexokinase 2 (Hk2) knockdown BMDC cells. (F) Ctr or Hk2 knockdown BMDCs were pulsed with 500 µg/mL ovalbumin (OVA) protein for 4 hours, washed twice, and then co-cultured with B3Z hybridoma cells for 16 hours. Interleukin 2 (IL2) secretion was measured by ELISA as an indicator for antigen cross-presentation capacity. (G) Control (Ctr) or Hk2 knockdown BMDCs were collected for cytofluorometric detection of DC activation and maturation markers. (H) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA (0.2 mg/kg) and oxaliplatin (OXA; 10 mg/kg), alone or in combination. (I, J) The tumor growth curves (I, mean±SEM) and Kaplan-Meier overall survival (J) of murine fibrosarcoma MCA205 cells in C57BL/6 mice (n=8–10 mice /group). (K) Schematic overview of the treatment of murine MCA205 fibrosarcoma with IKA plus OXA (Comb) and neutralizing antibodies to CD4 and CD8 (αCD4/CD8), alone or in combination. (L, M) The tumor growth curves (L, mean±SEM) and Kaplan-Meier overall survival (M) of murine fibrosarcoma MCA205 cells in immunocompetent and antibody-neutralized C57BL/6 mice (n=8–10 mice/group). Data are reported as the mean±SD of three replicates, and statistical analyses were performed with two-tailed unpaired Student’s t test (A, C, E, F, G), and two-way analysis of variance followed by the Holm-Šídák post hoc test (I, L). Log-rank test was used for survival comparison.

    Article Snippet: Antibodies for western blot: αHexokinase II (Cat# 2867) αPhospho-Zap-70 (Tyr319)/Syk (Tyr352) (Cat# 2701), αZap-70 (Cat# 2705), αPhospho-LAT (Tyr220) (Cat# 3584), and αLAT (Cat#45533) were purchased from Cell Signaling Technology (Danvers, Massachusetts, USA). αPhospho-LCK (Tyr394) (Cat#933102), αLCK (Cat# 601002) were from BioLegend (San Diego, California, USA).

    Techniques: Biomarker Discovery, Derivative Assay, Activation Assay, Flow Cytometry, Positive Control, Western Blot, Control, Knockdown, Cell Culture, Enzyme-linked Immunosorbent Assay, Two Tailed Test, Comparison